-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

Benzinga·08/17/2026 12:59:00
Listen to the news
Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.